文献速递心脑血管急症儿科与产科急症

左乙拉西坦与苯妥英作为儿童惊厥性癫痫持续状态二线治疗的多中心开放标签随机试验(EcLiPSE)

Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial.
PubMed 文献 · Lancet · 2019-04-17
一句话结论在儿童惊厥性癫痫持续状态中,左乙拉西坦终止发作不显著优于苯妥英(HR 1.20,95%CI 0.91-1.60;P=0.20),作者认为其可作二线首选替代。

EcLiPSE为英国30个急诊科开展的多中心、开放标签、随机试验,纳入6月龄至18岁以下需二线治疗的儿童惊厥性癫痫持续状态患者,1:1随机接受左乙拉西坦(40 mg/kg,5分钟静注)或苯妥英(20 mg/kg,至少20分钟静注)。主要终点为随机化至惊厥停止时间,改良意向治疗人群286例(左乙拉西坦152例、苯妥英134例)。左乙拉西坦组106例(70%)终止发作,苯妥英组86例(64%);中位时间左乙拉西坦35分钟 vs 苯妥英45分钟(HR 1.20,95%CI 0.91-1.60;P=0.20),差异未达统计学显著。作者认为,结合已知安全性及给药便利性,左乙拉西坦可作为儿童惊厥性癫痫持续状态二线抗惊厥药的合适替代。

要点

  • 6月龄至18岁以下儿童惊厥性癫痫持续状态需二线治疗时,左乙拉西坦40 mg/kg(5分钟)与苯妥英20 mg/kg(至少20分钟)随机对比,主要终点无显著差异。
  • 终止发作率:左乙拉西坦组106/152(70%) vs 苯妥英组86/134(64%);中位终止时间35分钟 vs 45分钟(HR 1.20,95%CI 0.91-1.60;P=0.20)。
  • 苯妥英组1例出现与研究治疗相关的严重不良反应(低血压视为危及生命,局灶性发作增多和意识下降视为医学上显著)。
  • 左乙拉西坦组1例在接受左乙拉西坦后加用苯妥英后死于灾难性脑水肿,原文判定与两种治疗无关。
  • 作者认为左乙拉西坦虽未显著优于苯妥英,但结合已知安全性及给药便利性,可作为儿童惊厥性癫痫持续状态二线首选抗惊厥药的合适替代。

适用人群与场景

  • 英国30个二级和三级医疗中心急诊科,年龄6月龄至18岁以下、需要二线治疗的儿童惊厥性癫痫持续状态患者。
  • 改良意向治疗分析排除随机化后不需二线治疗者及未提供知情同意者。

处置流程与药物剂量

  • 左乙拉西坦40 mg/kg,5分钟内静脉给药。
  • 苯妥英20 mg/kg,至少20分钟静脉给药。

红旗征与不能漏的情况

  • 苯妥英组1例出现与研究治疗相关的严重不良反应:低血压(视为立即危及生命的严重不良反应),以及局灶性发作增多和意识下降(视为医学上显著的疑似非预期严重不良反应)。
  • 左乙拉西坦组1例在接受左乙拉西坦后加用苯妥英后死于灾难性脑水肿,原文判定与两种治疗无关。

研究设计与关键结果

  • 多中心、开放标签、随机试验,英国30个急诊科,2015年7月17日至2018年4月7日筛查1432例,随机404例,改良意向治疗286例(左乙拉西坦152例、苯妥英134例)。
  • 主要终点(随机化至惊厥停止时间):左乙拉西坦组106例(70%)终止发作 vs 苯妥英组86例(64%);中位时间左乙拉西坦35分钟(IQR 20至不可评估) vs 苯妥英45分钟(IQR 24至不可评估),HR 1.20(95%CI 0.91-1.60;P=0.20),未达统计学显著。
  • 安全性:苯妥英组1例严重不良反应(低血压危及生命;局灶性发作增多和意识下降医学上显著);左乙拉西坦组1例死亡(灾难性脑水肿,与治疗无关)。

证据类型、等级与局限

  • 证据类型:多中心、开放标签、随机对照试验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,左乙拉西坦虽未显著优于苯妥英,但结合已知安全性及给药便利性,可作为儿童惊厥性癫痫持续状态二线首选抗惊厥药的合适替代。
  • 原文未据此给出其他推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Phenytoin is the recommended second-line intravenous anticonvulsant for treatment of paediatric convulsive status epilepticus in the UK; however, some evidence suggests that levetiracetam could be an effective and safer alternative. This trial compared the efficacy and safety of phenytoin and levetiracetam for second-line management of paediatric convulsive status epilepticus.

METHODS: This open-label, randomised clinical trial was undertaken at 30 UK emergency departments at secondary and tertiary care centres. Participants aged 6 months to under 18 years, with convulsive status epilepticus requiring second-line treatment, were randomly assigned (1:1) using a computer-generated randomisation schedule to receive levetiracetam (40 mg/kg over 5 min) or phenytoin (20 mg/kg over at least 20 min), stratified by centre. The primary outcome was time from randomisation to cessation of convulsive status epilepticus, analysed in the modified intention-to-treat population (excluding those who did not require second-line treatment after randomisation and those who did not provide consent). This trial is registered with ISRCTN, number ISRCTN22567894.

FINDINGS: Between July 17, 2015, and April 7, 2018, 1432 patients were assessed for eligibility. After exclusion of ineligible patients, 404 patients were randomly assigned. After exclusion of those who did not require second-line treatment and those who did not consent, 286 randomised participants were treated and had available data: 152 allocated to levetiracetam, and 134 to phenytoin. Convulsive status epilepticus was terminated in 106 (70%) children in the levetiracetam group and in 86 (64%) in the phenytoin group. Median time from randomisation to cessation of convulsive status epilepticus was 35 min (IQR 20 to not assessable) in the levetiracetam group and 45 min (24 to not assessable) in the phenytoin group (hazard ratio 1·20, 95% CI 0·91-1·60; p=0·20). One participant who received levetiracetam followed by phenytoin died as a result of catastrophic cerebral oedema unrelated to either treatment. One participant who received phenytoin had serious adverse reactions related to study treatment (hypotension considered to be immediately life-threatening [a serious adverse reaction] and increased focal seizures and decreased consciousness considered to be medically significant [a suspected unexpected serious adverse reaction]).

INTERPRETATION: Although levetiracetam was not significantly superior to phenytoin, the results, together with previously reported safety profiles and comparative ease of administration of levetiracetam, suggest it could be an appropriate alternative to phenytoin as the first-choice, second-line anticonvulsant in the treatment of paediatric convulsive status epilepticus.

FUNDING: National Institute for Health Research Health Technology Assessment programme.

来源:Lancet,查看原文。版权归原作者所有。

参考来源

  1. Lyttle MD, Rainford NEA, Gamble C, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet. 2019. PMID: 31005385. doi:10.1016/S0140-6736(19)30724-X

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。